Synagis Special Precautions

Allergic reactions including very rare anaphylaxis and anaphylactic shock have been reported following palivizumab administration. In some cases, fatalities have been reported (see Adverse Reactions).
Medications for the treatment of severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock should be available for immediate use following administration of palivizumab. If a severe hypersensitivity reaction occurs, therapy with palivizumab should be discontinued. As with other agents administered to this population, if milder hypersensitivity reactions occur, caution should be used on re-administration of palivizumab.
As with any intramuscular injection, SYNAGIS should be given with caution to patients with thrombocytopenia or any coagulation disorder.
The single-use vial of SYNAGIS does not contain a preservative. Injections should be given within six hours after reconstitution.
A moderate to severe acute infection or febrile illness may warrant delaying the use of SYNAGIS, unless, in the opinion of the physician, withholding SYNAGIS entails a greater risk. A mild febrile illness, such as a mild upper respiratory infection, is not usually reason to defer administration of SYNAGIS.
Effect on ability to drive and use machines: Not relevant.